BlackRock Amends Fate Therapeutics Stake, Filing 13G/A
Ticker: FATE · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | SC 13G/A |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, SC-13G/A
TL;DR
**BlackRock updated its FATE THERAPEUTICS INC stake as of Dec 31, 2023.**
AI Summary
BlackRock, Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating its ownership in FATE THERAPEUTICS INC as of December 31, 2023. This filing, Amendment No. 5, updates their previous disclosures regarding their stake in the biotechnology company. For investors, this matters because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in the company's future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's updated ownership in Fate Therapeutics, providing transparency on a major institutional investor's position, which can influence market sentiment.
Risk Assessment
Risk Level: low — This is a routine disclosure of institutional ownership and does not inherently present a direct risk to investors.
Analyst Insight
Investors should note BlackRock's continued presence as a major shareholder, but this filing alone doesn't provide enough detail to warrant immediate action. Further investigation into BlackRock's specific percentage ownership (not provided in this snippet) and any recent changes would be prudent.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person filing the SC 13G/A
- FATE THERAPEUTICS INC (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event which required the filing of this statement
- January 24, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- BlackRock will maintain a significant institutional stake in FATE THERAPEUTICS INC. (BlackRock, Inc.) — medium confidence, target: December 31, 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No: 5'.
Who is the 'subject company' in this filing?
The subject company is FATE THERAPEUTICS INC, identified by 'COMPANY CONFORMED NAME: FATE THERAPEUTICS INC' and CIK 0001434316.
Who is the 'reporting person' making this filing?
The reporting person is BlackRock, Inc., identified by 'COMPANY CONFORMED NAME: BlackRock Inc.' and CIK 0001364742.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required this filing was December 31, 2023, as stated in the filing.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of FATE THERAPEUTICS INC is 31189P102, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding FATE THERAPEUTICS INC (FATE).